Goldman Sachs Group Inc Intra Cellular Therapies, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 456,030 shares of ITCI stock, worth $38.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
456,030
Previous 588,181 22.47%
Holding current value
$38.9 Million
Previous $40.3 Million 17.23%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$67.99 - $80.84 $8.98 Million - $10.7 Million
-132,151 Reduced 22.47%
456,030 $33.3 Million
Q2 2024

Aug 13, 2024
SELL
$64.76 - $79.84 $11.5 Million - $14.2 Million
-178,246 Reduced 23.26%
588,181 $40.3 Million
Q1 2024

May 15, 2024
BUY
$64.37 - $75.65 $12.1 Million - $14.2 Million
187,812 Added 32.46%
766,427 $53 Million
Q4 2023

Feb 13, 2024
BUY
$46.37 - $73.65 $9.25 Million - $14.7 Million
199,503 Added 52.62%
578,615 $41.4 Million
Q3 2023

May 14, 2024
SELL
$52.09 - $64.1 $10.4 Million - $12.8 Million
-199,503 Reduced 34.48%
379,112 $19.7 Million
Q3 2023

Nov 14, 2023
BUY
$52.09 - $64.1 $2.28 Million - $2.8 Million
43,690 Added 13.03%
379,112 $19.7 Million
Q2 2023

May 14, 2024
SELL
$54.67 - $66.44 $6.54 Million - $7.95 Million
-119,692 Reduced 26.3%
335,422 $21.2 Million
Q2 2023

Aug 14, 2023
SELL
$54.67 - $66.44 $6.54 Million - $7.95 Million
-119,692 Reduced 26.3%
335,422 $21.2 Million
Q1 2023

May 14, 2024
BUY
$43.8 - $56.99 $4.41 Million - $5.74 Million
100,681 Added 28.41%
455,114 $24.6 Million
Q1 2023

May 11, 2023
BUY
$43.8 - $56.99 $4.41 Million - $5.74 Million
100,681 Added 28.41%
455,114 $24.6 Million
Q4 2022

May 14, 2024
SELL
$44.07 - $54.45 $12.9 Million - $15.9 Million
-292,813 Reduced 45.24%
354,433 $18.8 Million
Q4 2022

Feb 13, 2023
SELL
$44.07 - $54.45 $12.9 Million - $15.9 Million
-292,813 Reduced 45.24%
354,433 $18.8 Million
Q3 2022

May 14, 2024
BUY
$42.7 - $59.99 $766,550 - $1.08 Million
17,952 Added 2.85%
647,246 $30.1 Million
Q3 2022

Nov 10, 2022
BUY
$42.7 - $59.99 $766,550 - $1.08 Million
17,952 Added 2.85%
647,246 $30.1 Million
Q2 2022

May 14, 2024
BUY
$43.0 - $65.64 $2.18 Million - $3.33 Million
50,679 Added 8.76%
629,294 $35.9 Million
Q2 2022

Aug 15, 2022
BUY
$43.0 - $65.64 $6.47 Million - $9.88 Million
150,576 Added 31.45%
629,294 $35.9 Million
Q1 2022

May 16, 2022
BUY
$38.74 - $62.09 $9.43 Million - $15.1 Million
243,475 Added 103.5%
478,718 $29.3 Million
Q4 2021

Feb 14, 2022
SELL
$35.2 - $53.42 $12.4 Million - $18.8 Million
-351,743 Reduced 59.92%
235,243 $12.3 Million
Q3 2021

Nov 10, 2021
BUY
$28.72 - $42.49 $16.9 Million - $24.9 Million
586,986 New
586,986 $21.9 Million

Others Institutions Holding ITCI

# of Institutions
377
Shares Held
84.1M
Call Options Held
319K
Put Options Held
143K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.05B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email